InCarda Therapeutics said today that it raised $42 million in an oversubscribed Series B financing round led by Sofinnova and HealthCap.
Proceeds from the round are slated to support a Phase II trial of the company’s inhaled paroxysmal atrial fibrillation drug, InRhythm.
On December 11-12,DeviceTalks West is taking over Orange County's medtech industry with one of the most anticipated conferences of the winter, bringing you the best and brightest minds in the industry.
Dr. Robert Greenberg, Executive Chairman, Alfred E. Mann Foundation
Gary Guthart, President and Chief Executive Officer, Intuitive Surgical
Reggie Groves, CEO, REVA Medical
Use code KEYNOTE to save an additional 10%.